Literature DB >> 27206962

Cerebral vasomotor reactivity in reversible cerebral vasoconstriction syndrome.

Mehmet Akif Topcuoglu1,2, Suk-Tak Chan3, Gisele Sampaio Silva4, Eric Edward Smith5, Kenneth K Kwong3, Aneesh Bhim Singhal1.   

Abstract

Background Altered cerebrovascular tone is implicated in reversible cerebral vasoconstriction syndrome (RCVS). We evaluated vasomotor reactivity using bedside transcranial Doppler in RCVS patients. Methods In this retrospective case-control study, middle cerebral artery (MCA) blood flow velocities were compared at rest and in response to breath-hold in RCVS ( n = 8), Migraineurs ( n = 10), and non-headache Controls ( n = 10). Hyperventilation response was measured in RCVS. Results In RCVS, Breath Holding Index (BHI) was severely reduced in seven of eight patients and 14/16 MCAs; seven of 16 MCAs showed exhausted (BHI < 0.1) or inverted (BHI < 0) vasomotor reactivity. Mean BHI in RCVS (0.23 ± 0.5) was significantly lower than Migraine (1.52 ± 0.57) and Controls (1.51 ± 0.32), p < 0.001. Triphasic velocity responses were seen in all groups. The maximum Vmean decline during the middle negative phase was -15.5 ± 9.2% in RCVS, -15.4 ± 7% in Migraine, and -10.3 ± 5% in Controls ( p = 0.04). In the late positive phase, average Vmean increase was 6.2 ± 14% in RCVS, which was significantly lower ( p < 0.001) than Migraine (30.5 ± 11%) and Controls (30.2 ± 6%). With hyperventilation, RCVS patients showed 23% decrease in Vmean. Conclusion Cerebral arterial tone is abnormal in RCVS, with proximal vasoconstriction and abnormally reduced capacity for vasodilation. Further studies are needed to determine the utility of BHI to diagnose RCVS before angiographic reversibility is established, and to estimate prognosis.

Entities:  

Keywords:  Reversible cerebral vasoconstriction syndrome; breath-hold challenge; cerebrovascular reactivity; migraine; transcranial Doppler

Mesh:

Year:  2016        PMID: 27206962     DOI: 10.1177/0333102416650706

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  Right hemispheric reversible cerebral vasoconstriction syndrome in a patient with left hemispheric partial seizures.

Authors:  Gina S Perez; Justin McCaslin; Sadat Shamim
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

2.  Primary angiitis of the central nervous system and reversible cerebral vasoconstriction syndrome: analysis of the National Inpatient Sample.

Authors:  Hugo Lopez-Arevalo; Maria Emilia Romero Noboa; Dijo Joseph; Ehizogie Edigin; Shilpa Arora; Augustine Manadan
Journal:  Clin Rheumatol       Date:  2022-04-12       Impact factor: 3.650

3.  Cerebral endothelial dysfunction in reversible cerebral vasoconstriction syndrome: a case-control study.

Authors:  Hyun Ah Choi; Mi Ji Lee; Chin-Sang Chung
Journal:  J Headache Pain       Date:  2017-02-23       Impact factor: 7.277

4.  Cocaine Induced Bilateral Posterior Inferior Cerebellar Artery and Hippocampal Infarction.

Authors:  Naresh Mullaguri; Anusha Battineni; Aarti Narayan; Raviteja Guddeti
Journal:  Cureus       Date:  2018-05-04

5.  Marijuana and Microcirculation: A Review.

Authors:  Pramod Theetha Kariyanna; Leanna R Smith; Karishma Patwa; Moro O Salifu; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2020-06-05

6.  Clinical significance of centripetal propagation of vasoconstriction in patients with reversible cerebral vasoconstriction syndrome: A retrospective case-control study.

Authors:  Masami Shimoda; Shinri Oda; Hideaki Shigematsu; Kaori Hoshikawa; Masaaki Imai; Fuminari Komatsu; Akihiro Hirayama; Takahiro Osada
Journal:  Cephalalgia       Date:  2018-03-01       Impact factor: 6.292

Review 7.  Pathophysiology of reversible cerebral vasoconstriction syndrome.

Authors:  Shih-Pin Chen; Shuu-Jiun Wang
Journal:  J Biomed Sci       Date:  2022-09-21       Impact factor: 12.771

Review 8.  Posterior Reversible Encephalopathy Syndrome: A Review of the Literature.

Authors:  Yuya Ando; Yosuke Ono; Azusa Sano; Naoya Fujita; Sachiko Ono
Journal:  Intern Med       Date:  2021-07-17       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.